home / stock / trgnf / trgnf quote
Last: | $1.62 |
---|---|
Change Percent: | 0.0% |
Open: | $1.62 |
Close: | $1.62 |
High: | $1.62 |
Low: | $1.62 |
Volume: | 100 |
Last Trade Date Time: | 10/06/2023 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.62 | $1.62 | $1.62 | $1.62 | $1.62 | 100 | 10-06-2023 |
$1.85 | $1.85 | $1.85 | $1.85 | $1.85 | 200 | 09-05-2023 |
$1.8 | $1.8 | $1.8 | $1.8 | $1.8 | 100 | 08-14-2023 |
$1.9 | $1.9 | $1.9 | $1.9 | $1.9 | 600 | 08-07-2023 |
$2.05 | $2.05 | $2.05 | $2.05 | $2.05 | 100 | 07-20-2023 |
$2.1 | $2 | $2.1 | $2.1 | $2 | 2,200 | 06-20-2023 |
$2 | $2 | $2 | $2 | $2 | 150 | 06-19-2023 |
$2 | $2 | $2 | $2 | $2 | 150 | 06-16-2023 |
$2 | $0 | $2 | $0 | $0 | 50 | 06-08-2023 |
$2 | $2.04 | $2 | $2.04 | $2 | 300 | 06-05-2023 |
$2.05 | $2.05 | $2.05 | $2.05 | $2.05 | 200 | 04-04-2023 |
$2 | $2 | $2 | $2 | $2 | 200 | 03-16-2023 |
$0.0101 | $0.0101 | $0.0101 | $0.0101 | $0.0101 | 300 | 10-25-2022 |
$0.0101 | $0.0101 | $0.0101 | $0.0101 | $0.0101 | 250 | 08-30-2022 |
$2.15 | $2.15 | $2.15 | $2.15 | $2.15 | 150 | 08-09-2022 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 475 | 08-08-2022 |
$2.2 | $2.2 | $2.2 | $2.2 | $2.2 | 475 | 08-05-2022 |
$2.3 | $2.3 | $2.3 | $2.3 | $2.3 | 1,000 | 08-04-2022 |
$2.45 | $2.45 | $2.45 | $2.45 | $2.45 | 700 | 07-11-2022 |
$2.4499 | $2.45 | $2.4499 | $2.45 | $2.4499 | 750 | 07-07-2022 |
News, Short Squeeze, Breakout and More Instantly...
Transgene S.A. Company Name:
TRGNF Stock Symbol:
OTCMKTS Market:
Strasbourg, France, April 24, 2024, 5:45 p.m. CET - Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies, announced that the documentation related to the Combined General Meeting (ordinary and extraordinary sessions) of Transgene’s shar...
Extensive Phase I immunology data confirm strong immunogenicity of TG4050 in the adjuvant treatment of head and neck cancers. All treated patients remain disease-free after a median follow-up of 18.6 months. Phase II part of the trial to start enrolling patients in coming weeks. ...
2023 Full-year results and business update Lead program TG4050 to deliver data in 2024. Advancements in other clinical programs and Research and Innovation (R&I) activity to deliver news flow and fuel growth in Transgene’s portfolio over the next 24 month...